Lymphocytopenia following adjuvant radiotherapy for breast cancer

Abstract

Objective: We retrospectively analyzed breast cancer patients who received adjuvant radiotherapy to determine the incidence of lymphocytopenia and its risk factors.

Methods: We reviewed 812 patients with breast cancer who received postoperative radiotherapy. Patients were divided into two groups based on the use of chemotherapy, and a generalized linear regression model was used to explore predictive factors for grade 2 or higher lymphocytopenia. We also examined the effect of lymphocytopenia on overall survival.

Results: Grade 2 or higher lymphocytopenia was observed in 19.4% of patients who did not receive chemotherapy and 45.1% of patients who received chemotherapy. In multivariate analysis, bilateral disease, regional lymph node irradiation, and baseline lymphocytopenia were associated with lymphocytopenia in patients who did not receive cytotoxic chemotherapy. Regional lymph node irradiation, baseline lymphocytopenia, use of antimetabolites, and use of molecular-targeted agents were associated with lymphocytopenia in patients treated with chemotherapy. In the survival analysis, lymphocytopenia was associated with worse overall survival only in patients treated with cytotoxic chemotherapy (p = 0.039), and not in patients who did not receive chemotherapy (p = 0.77).

Conclusion: The analysis revealed the incidence and risk factors of lymphocytopenia after postoperative radiotherapy in patients with breast cancer.

Keywords

breast cancer / hematotoxicity / lymphopenia / radiotherapy / volumetric modulated arc therapy

References

[1] StandishLJ, Torkelson C, HamillFA, et al. Immune defects in breast cancer patients after radiotherapy. J Soc Integr Oncol. 2008;6(3):110-121.

[2] DaiD, TianQ, ShuiY, Li J, WeiQ. The impact of radiation induced lymphopenia in the prognosis of head and neck cancer: A systematic review and meta-analysis. Radiother Oncol. 2022;168:28-36.

[3] ZhangY, HanN, ZengX, et al. Impact of Platelets to Lymphocytes Ratio and Lymphocytes during Radical Concurrent Radiotherapy and Chemotherapy on Patients with Nonmetastatic Esophageal Squamous Cell Carcinoma. J Oncol. 2022;2022:3412349.

[4] UpadhyayR, Venkatesulu BP, GiridharP, et al. Risk and impact of radiation related lymphopenia in lung cancer: A systematic review and meta-analysis. Radiother Oncol. 2021;157:225-233.

[5] YoonCI, HwangJ, KimD, et al. Prognostic impact of radiotherapy-induced-lymphopenia in patients treated with breast-conservative surgery. Sci Rep. 2023;13(1):14372.

[6] ChenF, MaL, WangQ, et al. Chemotherapy is a risk factor of lymphopenia before adjuvant radiotherapy in breast cancer. Cancer Rep. 2022;5(7):e1525.

[7] SunGY, WangSL, SongYW, et al. Radiation-Induced Lymphopenia Predicts Poorer Prognosis in Patients With Breast Cancer: A Post Hoc Analysis of a Randomized Controlled Trial of Postmastectomy Hypofractionated Radiation Therapy. Int J Radiat Oncol Biology Phys. 2020;108(1):277-285.

[8] ChenF, YuH, ZhangH, et al. Risk factors for radiation induced lymphopenia in patients with breast cancer receiving adjuvant radiotherapy. Ann Transl Medicine. 2021;9(16):1288.

[9] ChenF, JinJY, HuiTSK, et al. Radiation Induced Lymphopenia Is Associated With the Effective Dose to the Circulating Immune Cells in Breast Cancer. Front Oncol. 2022;12:768956.

[10] YuH, ChenF, LamKO, et al. Potential Determinants for Radiation-Induced Lymphopenia in Patients With Breast Cancer Using Interpretable Machine Learning Approach. Front Immunol. 2022;13:768811.

[11] TakedaK, Umezawa R, YamamotoT, et al. Acute hematologic toxicity of radiation therapy – a comprehensive analysis and predictive nomogram. J Radiat Res. 2023;64(6):954-961.

[12] GrossmanSA, YeX, LesserG, et al. Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide. Clin Cancer Res. 2011;17(16):5473-5480.

[13] WildAT, YeX, EllsworthSG, et al. The Association Between Chemoradiation-related Lymphopenia and Clinical Outcomes in Patients With Locally Advanced Pancreatic Adenocarcinoma. Am J Clin Oncol. 2015;38(3):259-265.

[14] van RossumPSN, DengW, RoutmanDM, et al. Prediction of Severe Lymphopenia During Chemoradiation Therapy for Esophageal Cancer: Development and Validation of a Pretreatment Nomogram. Pract Radiat Oncol. 2020;10(1):e16-e26.

[15] SumiyaT, Ishikawa H, HiroshimaY, et al. The impact of lymphopenia during chemoradiotherapy using photons or protons on the clinical outcomes of esophageal cancer patients. J Radiat Res. 2021;62(6):1045-1055.

[16] JinJY, HuC, XiaoY, et al. Higher Radiation Dose to the Immune Cells Correlates with Worse Tumor Control and Overall Survival in Patients with Stage III NSCLC: A Secondary Analysis of RTOG0617. Cancers. 2021;13(24):6193.

[17] XuC, JinJY, ZhangM, et al. The impact of the effective dose to immune cells on lymphopenia and survival of esophageal cancer after chemoradiotherapy. Radiother Oncol. 2020;146:180-186.

[18] NakamuraN, Kusunoki Y, AkiyamaM. Radiosensitivity of CD4 or CD8 positive human T-lymphocytes by an in vitro colony formation assay. Radiat Res. 1990;123(2):224-227.

RIGHTS & PERMISSIONS

2024 The Authors. Precision Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Shandong Cancer Hospital & Institute.